Sanofi (SNY) Form 6-K — Sep 17, 2026
Sanofi and Cheplapharm announced their intention to create a strategic partnership under which Cheplapharm would take over a selection of 20 mature medicines and three manufacturing sites worldwide from Sanofi, with Sanofi receiving a 26.4% equity stake in Cheplapharm in return. The divested portfolio includes Lovenox/Clexane (enoxaparin, excluding the US). The three sites are Csanyikvölgy in Hungary (c.400 employees), Jurong in Singapore (c.100 employees), and Ploërmel in France (c.65 employees), with existing employment arrangements and collective agreements maintained.
Key figures
- Medicines divested
- 20
- France site employees
- c.65
- Hungary site employees
- c.400
- Collaboration start year
- 2014
- Expected full completion
- Q3 2027
- Singapore site employees
- c.100
- Commercial transfer start
- Q1 2027
- Manufacturing sites transferred
- 3
- Cheplapharm cumulative investment
- €6.2 billion since inception
- Cheplapharm marketing authorizations
- 3440
- Equity stake received in cheplapharm
- 26.4%
- Cheplapharm products acquired since 2015
- nearly 100
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.